Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Mizuho enthusiasm 'tempered somewhat' after speaking to Eli Lilly » 13:20
06/24/21
06/24
13:20
06/24/21
13:20
LLY

Eli Lilly

$234.02 /

+16.95 (+7.81%)

, BIIB

Biogen

$354.46 /

-17.36 (-4.67%)

Mizuho analyst Vamil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

BIIB Biogen
$354.46 /

-17.36 (-4.67%)

LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

09:17 Today Cantor Fitzgerald
Eli Lilly price target raised to $300 from $245 at Cantor Fitzgerald
08:29 Today Cowen
Eli Lilly price target raised to $250 from $235 at Cowen
06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
BIIB Biogen
$354.46 /

-17.36 (-4.67%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

BIIB Biogen
$354.46 /

-17.36 (-4.67%)

LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

BIIB Biogen
$354.46 /

-17.36 (-4.67%)

LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

BIIB Biogen
$354.46 /

-17.36 (-4.67%)

LLY Eli Lilly
$234.02 /

+16.95 (+7.81%)

BIIB Biogen
$354.46 /

-17.36 (-4.67%)

On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:38
06/24/21
06/24
12:38
06/24/21
12:38
EURMF

Europcar Mobility

/

+

, CDXC

ChromaDex

$8.69 /

-0.26 (-2.91%)

, LLY

Eli Lilly

$232.56 /

+15.49 (+7.14%)

, BIIB

Biogen

$349.79 /

-22.03 (-5.92%)

, EBAY

eBay

$66.36 /

+1.05 (+1.61%)

, CLOV

Clover Health

$13.82 /

+0.01 (+0.07%)

, ENFA

890 5th Avenue Partners

$9.86 /

+0.07 (+0.72%)

, MSFT

Microsoft

$267.67 /

+2.43 (+0.92%)

, C

Citi

$70.66 /

+1.03 (+1.48%)

, VWAGY

Volkswagen

$33.87 /

-0.5298 (-1.54%)

, JPM

JPMorgan

$151.96 /

+0.84 (+0.56%)

, ABC

AmerisourceBergen

$115.70 /

-0.09 (-0.08%)

, ACN

Accenture

$291.25 /

+5.52 (+1.93%)

, RAD

Rite Aid

$17.59 /

-2.78 (-13.65%)

, KBH

KB Home

$40.69 /

-2.68 (-6.18%)

, CCL

Carnival

$27.65 /

-0.49 (-1.74%)

, DRI

Darden

$139.82 /

+4.345 (+3.21%)

, DLTR

Dollar Tree

$98.79 /

-2.7 (-2.66%)

, GSK

GlaxoSmithKline

$39.79 /

-0.07 (-0.18%)

, MGM

MGM Resorts

$44.50 /

+1.38 (+3.20%)

, ERIC

Ericsson

$12.54 /

+0.115 (+0.93%)

, ATVI

Activision Blizzard

$92.38 /

+1.6 (+1.76%)

, TTWO

Take-Two

$174.70 /

+2.77 (+1.61%)

, EA

Electronic Arts

$138.10 /

-0.6 (-0.43%)

Get caught up quickly on…

ShowHide Related Items >><<
VWAGY Volkswagen
$33.87 /

-0.5298 (-1.54%)

TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

KBH KB Home
$40.69 /

-2.68 (-6.18%)

JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

EURMF Europcar Mobility
/

+

ERIC Ericsson
$12.54 /

+0.115 (+0.93%)

ENFA 890 5th Avenue Partners
$9.86 /

+0.07 (+0.72%)

EBAY eBay
$66.36 /

+1.05 (+1.61%)

EA Electronic Arts
$138.10 /

-0.6 (-0.43%)

DRI Darden
$139.82 /

+4.345 (+3.21%)

DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

CDXC ChromaDex
$8.69 /

-0.26 (-2.91%)

CCL Carnival
$27.65 /

-0.49 (-1.74%)

C Citi
$70.66 /

+1.03 (+1.48%)

BIIB Biogen
$349.79 /

-22.03 (-5.92%)

ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

ACN Accenture
$291.25 /

+5.52 (+1.93%)

ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

EURMF Europcar Mobility
/

+

05/07/21 Societe Generale
Europcar Mobility upgraded to Buy from Hold at Societe Generale
05/07/21 Societe Generale
Europcar Mobility upgraded to Buy from Hold at Societe Generale
03/03/21 HSBC
Europcar Mobility upgraded to Hold from Reduce at HSBC
03/03/21 HSBC
Europcar Mobility upgraded to Hold from Reduce at HSBC
CDXC ChromaDex
$8.69 /

-0.26 (-2.91%)

06/07/21 H.C. Wainwright
ChromaDex sales momentum should accelerate, says H.C. Wainwright
03/16/21 H.C. Wainwright
ChromaDex price target raised to $16 from $7 at H.C. Wainwright
03/08/21 B. Riley
ChromaDex price target raised to $18 from $7 at B. Riley Securities
10/07/20 Oppenheimer
ChromaDex price target raised to $9 from $6 at Oppenheimer
LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

09:17 Today Cantor Fitzgerald
Eli Lilly price target raised to $300 from $245 at Cantor Fitzgerald
08:29 Today Cowen
Eli Lilly price target raised to $250 from $235 at Cowen
06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
BIIB Biogen
$349.79 /

-22.03 (-5.92%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
EBAY eBay
$66.36 /

+1.05 (+1.61%)

06/16/21 Baird
eBay volume appears to be tracking in-line, says Baird
05/03/21 BMO Capital
eBay price target lowered to $63 from $67 at BMO Capital
04/29/21
Fly Intel: Top five analyst downgrades
04/29/21 Wedbush
eBay downgraded to Neutral at Wedbush on lower visibility into post-COVID GMV
CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

06/10/21 BofA
Clover Health downgraded to Underperform from Neutral at BofA
05/18/21 Citi
Clover Health price target lowered to $10 from $13 at Citi
05/17/21 BofA
Clover Health downgraded to Neutral at BofA after guidance cut
05/17/21 BofA
Clover Health downgraded to Neutral from Buy at BofA
ENFA 890 5th Avenue Partners
$9.86 /

+0.07 (+0.72%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

06/23/21 Wedbush
Microsoft price target raised to $325 from $310 at Wedbush
06/16/21 William Blair
Microsoft gaming news opportunity not threat to Unity, says William Blair
06/15/21 Oppenheimer
Turtle Beach price target raised to $45 from $40 at Oppenheimer
06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
C Citi
$70.66 /

+1.03 (+1.48%)

06/08/21 Wells Fargo
Citi price target raised to $95 from $88 at Wells Fargo
05/03/21 JPMorgan
Citi price target raised to $77.50 from $74.50 at JPMorgan
04/13/21 Morgan Stanley
Citi price target raised to $89 from $81 at Morgan Stanley
04/09/21 Jefferies
Citi price target raised to $85 from $75 at Jefferies
VWAGY Volkswagen
$33.87 /

-0.5298 (-1.54%)

06/22/21 Piper Sandler
Electric vehicles will represent 94% of new car sales by 2040, says Piper
05/20/21 Citi
Volkswagen resumed with a Buy at Citi
05/10/21 Wedbush
Tesla demand looks robust so far in Q2 despite rising competition, says Wedbush
05/07/21 JPMorgan
Volkswagen price target lowered to EUR 245 from EUR 255 at JPMorgan
JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

06/15/21 BMO Capital
JPMorgan price target trimmed to $139 at BMO Capital on reduced NII view
06/14/21 Evercore ISI
Synchrony price target raised to $56 from $49 at Evercore ISI
06/08/21 Wells Fargo
JPMorgan price target raised to $200 from $195 at Wells Fargo
05/06/21 JMP Securities
Walker & Dunlop price target raised to $130 from $70 at JMP Securities
ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

08:23 Today BofA
BofA 'quite skeptical' of claim AmerisourceBergen looking at Parexel
05/06/21 Barclays
AmerisourceBergen price target raised to $130 from $122 at Barclays
03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
ACN Accenture
$291.25 /

+5.52 (+1.93%)

06/23/21 Exane BNP Paribas
Accenture upgraded to Outperform from Neutral at Exane BNP Paribas
06/21/21 Jefferies
Accenture initiated with a Hold at Jefferies
06/15/21 Societe Generale
Accenture price target raised to $329 from $313 at Societe Generale
06/10/21 Susquehanna
Accenture business more driven by Artificial Intelligence, says Susquehanna
RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

06/22/21 Deutsche Bank
Rite Aid price target lowered to $18 from $27 at Deutsche Bank
05/26/21 Deutsche Bank
Amazon unlikely to enter retail pharmacy business, says Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
KBH KB Home
$40.69 /

-2.68 (-6.18%)

06:17 Today RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
04/15/21 Wells Fargo
KB Home initiated with an Overweight at Wells Fargo
03/29/21 Argus
KB Home's new orders were 'stellar', says Argus
CCL Carnival
$27.65 /

-0.49 (-1.74%)

10:41 Today William Blair
Carnival's stock already prices in recovery, says William Blair
06/17/21 JPMorgan
Carnival price target raised to $36 from $33 at JPMorgan
06/16/21 Wolfe Research
Wolfe upgrades 'Big 3' cruise stocks on improving booking momentum
06/16/21 Wolfe Research
Carnival upgraded to Outperform from Peer Perform at Wolfe Research
DRI Darden
$139.82 /

+4.345 (+3.21%)

06/22/21 Baird
Darden risk/reward remains attractive, says Baird
06/22/21 RBC Capital
Darden price target raised to $162 from $158 at RBC Capital
06/09/21 Truist
Darden price target raised to $170 from $158 at Truist
06/01/21 Barclays
Darden price target lowered to $157 from $164 at Barclays
DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

09:57 Today
Fly Intel: Top five analyst downgrades
06:22 Today Piper Sandler
Piper downgrades Dollar Tree on inability to pass on inflation pressures
06:08 Today Piper Sandler
Dollar Tree downgraded to Neutral from Overweight at Piper Sandler
05/28/21 BMO Capital
Dollar Tree price target lowered to $108 from $115 at BMO Capital
GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

06:04 Today Deutsche Bank
Deutsche Bank upgrades GSK to Hold on 'obviously improving' story
06/23/21 Deutsche Bank
GlaxoSmithKline upgraded to Hold from Sell at Deutsche Bank
06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
06/11/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,300 GBp at Deutsche Bank
MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

09:57 Today
Fly Intel: Top five analyst upgrades
05:44 Today Deutsche Bank
Deutsche upgrades MGM Resorts to Buy on margin upside potential
05:19 Today Deutsche Bank
MGM Resorts upgraded to Buy from Hold at Deutsche Bank
06/10/21 JPMorgan
MGM Resorts price target raised to $52 from $47 at JPMorgan
ERIC Ericsson
$12.54 /

+0.115 (+0.93%)

05:07 Today UBS
Ericsson downgraded to Sell from Neutral at UBS
05/24/21 BofA
Ericsson removed from US 1 List at BofA
05/07/21 Morgan Stanley
Ericsson downgraded to Equal Weight from Overweight at Morgan Stanley
ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

09:57 Today
Fly Intel: Top five analyst initiations
06:36 Today MoffettNathanson
Electronic Arts initiated with a Neutral at MoffettNathanson
06:33 Today MoffettNathanson
Activision Blizzard initiated with a Buy at MoffettNathanson
05/11/21 BMO Capital
Activision Blizzard upgraded to Outperform from Market Perform at BMO Capital
TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

06:35 Today MoffettNathanson
Take-Two initiated with a Buy at MoffettNathanson
06/21/21 Benchmark
Benchmark would be opportunistic amid recent Take-Two pullback
06/03/21
Fly Intel: Top five analyst upgrades
EA Electronic Arts
$138.10 /

-0.6 (-0.43%)

06/23/21 Truist
Electronic Arts deal for Playdemic consistent with strategy, says Truist
06/21/21 Benchmark
Electronic Arts a buy following E3, says Benchmark
VWAGY Volkswagen
$33.87 /

-0.5298 (-1.54%)

TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

KBH KB Home
$40.69 /

-2.68 (-6.18%)

JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

ERIC Ericsson
$12.54 /

+0.115 (+0.93%)

EBAY eBay
$66.36 /

+1.05 (+1.61%)

EA Electronic Arts
$138.10 /

-0.6 (-0.43%)

DRI Darden
$139.82 /

+4.345 (+3.21%)

DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

CDXC ChromaDex
$8.69 /

-0.26 (-2.91%)

CCL Carnival
$27.65 /

-0.49 (-1.74%)

C Citi
$70.66 /

+1.03 (+1.48%)

BIIB Biogen
$349.79 /

-22.03 (-5.92%)

ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

ACN Accenture
$291.25 /

+5.52 (+1.93%)

ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

  • 23
    Feb
VWAGY Volkswagen
$33.87 /

-0.5298 (-1.54%)

TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

KBH KB Home
$40.69 /

-2.68 (-6.18%)

JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

ERIC Ericsson
$12.54 /

+0.115 (+0.93%)

ENFA 890 5th Avenue Partners
$9.86 /

+0.07 (+0.72%)

EBAY eBay
$66.36 /

+1.05 (+1.61%)

EA Electronic Arts
$138.10 /

-0.6 (-0.43%)

DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

CDXC ChromaDex
$8.69 /

-0.26 (-2.91%)

CCL Carnival
$27.65 /

-0.49 (-1.74%)

C Citi
$70.66 /

+1.03 (+1.48%)

BIIB Biogen
$349.79 /

-22.03 (-5.92%)

ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

VWAGY Volkswagen
$33.87 /

-0.5298 (-1.54%)

TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

KBH KB Home
$40.69 /

-2.68 (-6.18%)

JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

ENFA 890 5th Avenue Partners
$9.86 /

+0.07 (+0.72%)

EBAY eBay
$66.36 /

+1.05 (+1.61%)

DRI Darden
$139.82 /

+4.345 (+3.21%)

DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

CDXC ChromaDex
$8.69 /

-0.26 (-2.91%)

CCL Carnival
$27.65 /

-0.49 (-1.74%)

C Citi
$70.66 /

+1.03 (+1.48%)

BIIB Biogen
$349.79 /

-22.03 (-5.92%)

ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

ACN Accenture
$291.25 /

+5.52 (+1.93%)

ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

TTWO Take-Two
$174.70 /

+2.77 (+1.61%)

RAD Rite Aid
$17.59 /

-2.78 (-13.65%)

MSFT Microsoft
$267.67 /

+2.43 (+0.92%)

MGM MGM Resorts
$44.50 /

+1.38 (+3.20%)

LLY Eli Lilly
$232.56 /

+15.49 (+7.14%)

KBH KB Home
$40.69 /

-2.68 (-6.18%)

JPM JPMorgan
$151.96 /

+0.84 (+0.56%)

GSK GlaxoSmithKline
$39.79 /

-0.07 (-0.18%)

ERIC Ericsson
$12.54 /

+0.115 (+0.93%)

EBAY eBay
$66.36 /

+1.05 (+1.61%)

EA Electronic Arts
$138.10 /

-0.6 (-0.43%)

DRI Darden
$139.82 /

+4.345 (+3.21%)

DLTR Dollar Tree
$98.79 /

-2.7 (-2.66%)

CLOV Clover Health
$13.82 /

+0.01 (+0.07%)

CCL Carnival
$27.65 /

-0.49 (-1.74%)

C Citi
$70.66 /

+1.03 (+1.48%)

BIIB Biogen
$349.79 /

-22.03 (-5.92%)

ATVI Activision Blizzard
$92.38 /

+1.6 (+1.76%)

ACN Accenture
$291.25 /

+5.52 (+1.93%)

ABC AmerisourceBergen
$115.70 /

-0.09 (-0.08%)

Conference/Events
Truist healthcare/pharma analysts hold an analyst/industry conference call » 09:55
06/24/21
06/24
09:55
06/24/21
09:55
BIIB

Biogen

$352.53 /

-19.29 (-5.19%)

Healthcare &…

Healthcare & Pharmaceutical Analysts discuss the FDA's Complete Response Letter (CRL) in their decision to approve Biogen's drug for Alzheimer's, Aduhelm, on an Analyst/Industry conference call to be held on June 24 at 11 am.

ShowHide Related Items >><<
BIIB Biogen
$352.53 /

-19.29 (-5.19%)

BIIB Biogen
$352.53 /

-19.29 (-5.19%)

08:29 Today Cowen
Eli Lilly price target raised to $250 from $235 at Cowen
06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
BIIB Biogen
$352.53 /

-19.29 (-5.19%)

BIIB Biogen
$352.53 /

-19.29 (-5.19%)

BIIB Biogen
$352.53 /

-19.29 (-5.19%)

BIIB Biogen
$352.53 /

-19.29 (-5.19%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
06/24/21
06/24
08:55
06/24/21
08:55
LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

, PLTR

Palantir

$26.26 /

+0.86 (+3.39%)

, MGM

MGM Resorts

$43.12 /

+0.82 (+1.94%)

, MRIN

Marin Software

$1.67 /

+ (+0.00%)

, ACN

Accenture

$285.69 /

+0.19 (+0.07%)

, DRI

Darden

$135.42 /

-0.17 (-0.13%)

, RAD

Rite Aid

$20.37 /

+0.48 (+2.41%)

, KBH

KB Home

$43.35 /

+0.1 (+0.23%)

, BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

, PRTG

Portage Biotech

$35.28 /

+2.38 (+7.23%)

Check out this morning's…

ShowHide Related Items >><<
RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

PLTR Palantir
$26.26 /

+0.86 (+3.39%)

MRIN Marin Software
$1.67 /

+ (+0.00%)

MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

KBH KB Home
$43.35 /

+0.1 (+0.23%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

ACN Accenture
$285.69 /

+0.19 (+0.07%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

08:29 Today Cowen
Eli Lilly price target raised to $250 from $235 at Cowen
06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
PLTR Palantir
$26.26 /

+0.86 (+3.39%)

05/12/21 Wolfe Research
Palantir price target lowered to $20 from $23 at Wolfe Research
05/12/21 Morgan Stanley
Palantir building toward more durable growth, but priced in, says Morgan Stanley
05/12/21 Goldman Sachs
Goldman 'encouraged' by 'noteworthy' Q1 from Palantir, keeps Buy
05/12/21 Citi
Palantir price target raised to $17 from $15 at Citi
MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

05:44 Today Deutsche Bank
Deutsche upgrades MGM Resorts to Buy on margin upside potential
05:19 Today Deutsche Bank
MGM Resorts upgraded to Buy from Hold at Deutsche Bank
06/10/21 JPMorgan
MGM Resorts price target raised to $52 from $47 at JPMorgan
05/18/21
Fly Intel: Top five analyst upgrades
MRIN Marin Software
$1.67 /

+ (+0.00%)

ACN Accenture
$285.69 /

+0.19 (+0.07%)

06/23/21 Exane BNP Paribas
Accenture upgraded to Outperform from Neutral at Exane BNP Paribas
06/21/21 Jefferies
Accenture initiated with a Hold at Jefferies
06/15/21 Societe Generale
Accenture price target raised to $329 from $313 at Societe Generale
06/10/21 Susquehanna
Accenture business more driven by Artificial Intelligence, says Susquehanna
DRI Darden
$135.42 /

-0.17 (-0.13%)

06/22/21 Baird
Darden risk/reward remains attractive, says Baird
06/22/21 RBC Capital
Darden price target raised to $162 from $158 at RBC Capital
06/09/21 Truist
Darden price target raised to $170 from $158 at Truist
06/01/21 Barclays
Darden price target lowered to $157 from $164 at Barclays
RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

06/22/21 Deutsche Bank
Rite Aid price target lowered to $18 from $27 at Deutsche Bank
05/26/21 Deutsche Bank
Amazon unlikely to enter retail pharmacy business, says Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
KBH KB Home
$43.35 /

+0.1 (+0.23%)

06:17 Today RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
04/15/21 Wells Fargo
KB Home initiated with an Overweight at Wells Fargo
03/29/21 Argus
KB Home's new orders were 'stellar', says Argus
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
PRTG Portage Biotech
$35.28 /

+2.38 (+7.23%)

RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

PLTR Palantir
$26.26 /

+0.86 (+3.39%)

MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

KBH KB Home
$43.35 /

+0.1 (+0.23%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

ACN Accenture
$285.69 /

+0.19 (+0.07%)

  • 24
    Jun
RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

PLTR Palantir
$26.26 /

+0.86 (+3.39%)

MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

KBH KB Home
$43.35 /

+0.1 (+0.23%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

PLTR Palantir
$26.26 /

+0.86 (+3.39%)

MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

KBH KB Home
$43.35 /

+0.1 (+0.23%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

ACN Accenture
$285.69 /

+0.19 (+0.07%)

RAD Rite Aid
$20.37 /

+0.48 (+2.41%)

PLTR Palantir
$26.26 /

+0.86 (+3.39%)

MGM MGM Resorts
$43.12 /

+0.82 (+1.94%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

KBH KB Home
$43.35 /

+0.1 (+0.23%)

DRI Darden
$135.42 /

-0.17 (-0.13%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

ACN Accenture
$285.69 /

+0.19 (+0.07%)

Recommendations
Eli Lilly price target raised to $250 from $235 at Cowen » 08:29
06/24/21
06/24
08:29
06/24/21
08:29
LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

, BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

Cowen analyst Steve Scala…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

Hot Stocks
Eli Lilly jumps on expedited plans for Alzheimer's drug, Biogen falls » 07:22
06/24/21
06/24
07:22
06/24/21
07:22
LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

, BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

Eli Lilly (LLY) announced…

Eli Lilly (LLY) announced that the Food and Drug Administration granted Breakthrough Therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease. Lilly intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. The safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing Phase 3 study TRAILBLAZER-ALZ 2, the company said in a statement. The Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic Alzheimer's. Shares of Eli Lilly are up 9%, or $18.50, to $235.60 following the news. Shares of Biogen (BIIB), who recently received FDA approval for its Alzheimer's treatment, are down 6% to $350.02 in premarket trading.

ShowHide Related Items >><<
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

Conference/Events
Truist healthcare/pharma analysts hold an analyst/industry conference call » 04:55
06/24/21
06/24
04:55
06/24/21
04:55
BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

Healthcare &…

Healthcare & Pharmaceutical Analysts discuss the FDA's Complete Response Letter (CRL) in their decision to approve Biogen's drug for Alzheimer's, Aduhelm, on an Analyst/Industry conference call to be held on June 24 at 11 am.

ShowHide Related Items >><<
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

BIIB Biogen
$371.82 /

-2.77 (-0.74%)

Yesterday
Hot Stocks
Eisai, Biogen: FDA grants Breakthrough Therapy designation for lecanemab » 16:07
06/23/21
06/23
16:07
06/23/21
16:07
ESALY

Eisai

$107.63 /

-6.37 (-5.59%)

, BIIB

Biogen

$371.75 /

-2.84 (-0.76%)

Eisai (ESALY) and Biogen…

Eisai (ESALY) and Biogen (BIIB) announced that the U.S. FDA has granted Breakthrough Therapy designation for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of Alzheimer's disease.

ShowHide Related Items >><<
ESALY Eisai
$107.63 /

-6.37 (-5.59%)

BIIB Biogen
$371.75 /

-2.84 (-0.76%)

ESALY Eisai
$107.63 /

-6.37 (-5.59%)

06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
BIIB Biogen
$371.75 /

-2.84 (-0.76%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
BIIB Biogen
$371.75 /

-2.84 (-0.76%)

BIIB Biogen
$371.75 /

-2.84 (-0.76%)

ESALY Eisai
$107.63 /

-6.37 (-5.59%)

BIIB Biogen
$371.75 /

-2.84 (-0.76%)

BIIB Biogen
$371.75 /

-2.84 (-0.76%)

Conference/Events
Truist healthcare/pharma analysts hold an analyst/industry conference call » 13:02
06/23/21
06/23
13:02
06/23/21
13:02
BIIB

Biogen

$366.01 /

-8.58 (-2.29%)

Healthcare &…

Healthcare & Pharmaceutical Analysts discuss the FDA's Complete Response Letter (CRL) in their decision to approve Biogen's drug for Alzheimer's, Aduhelm, on an Analyst/Industry conference call to be held on June 24 at 11 am.

ShowHide Related Items >><<
BIIB Biogen
$366.01 /

-8.58 (-2.29%)

BIIB Biogen
$366.01 /

-8.58 (-2.29%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
BIIB Biogen
$366.01 /

-8.58 (-2.29%)

BIIB Biogen
$366.01 /

-8.58 (-2.29%)

BIIB Biogen
$366.01 /

-8.58 (-2.29%)

BIIB Biogen
$366.01 /

-8.58 (-2.29%)

Hot Stocks
Biogen says engaging with public, private payers to support access to Aduhelm » 08:07
06/23/21
06/23
08:07
06/23/21
08:07
BIIB

Biogen

$374.45 /

-6.38 (-1.68%)

, ESALY

Eisai

$114.00 /

+3.31 (+2.99%)

Biogen (BIIB) and Eisai…

Biogen (BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co. (EASLY), issued a statement to for the Alzheimer's disease community, stating in part: "On June 7, 2021, Aduhelm 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration. We are committed to responding to questions from the Alzheimer's disease community and providing more details about our plans... We have determined the launch price of Aduhelm based on our belief in the impact of treatment as well as the size of the appropriate patient population based on the entry criteria of our clinical trials. In the event that our fundamental assumptions on population size and rate of adoption are significantly different than expected, we stand ready to work with public and private payers to address pricing in order to achieve both patient access and support budget sustainability. We have been engaging directly with public and private payers and health systems to ensure coverage policies support access for appropriate patients... We are committed to engaging with CMS on innovative price and access agreements, including but not limited to, volume-based agreements that would help support continued sustainability of Medicare budgets. As part of our commitment to budget sustainability, Biogen will not be increasing the price of Aduhelm in the first four years following launch. We are committed to providing access to Aduhelm for patients across a spectrum of financial situations. We operate within the existing health insurance and legal system that limits the company's ability to subsidize out of pocket expenses for Medicare patients while generally allowing such assistance for commercially insured patients." Reference Link

ShowHide Related Items >><<
ESALY Eisai
$114.00 /

+3.31 (+2.99%)

BIIB Biogen
$374.45 /

-6.38 (-1.68%)

BIIB Biogen
$374.45 /

-6.38 (-1.68%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler
ESALY Eisai
$114.00 /

+3.31 (+2.99%)

06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
BIIB Biogen
$374.45 /

-6.38 (-1.68%)

BIIB Biogen
$374.45 /

-6.38 (-1.68%)

ESALY Eisai
$114.00 /

+3.31 (+2.99%)

BIIB Biogen
$374.45 /

-6.38 (-1.68%)

BIIB Biogen
$374.45 /

-6.38 (-1.68%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.